Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.49 |
| ▸ | IL1RN | P18510 | 2/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.47 |
| ▸ | VEGFA | P15692 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 3/20 | 0.47 |
| ▸ | MMP9 | P14780 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10715060 | 0.94 | ERAP2 (0.48) | KDM4ESMN1; SMN2ERAP2IL1RNERAP1 | |
| SCHEMBL10715057 | 0.90 | ERAP2 (0.46) | KDM4ESMN1; SMN2ERAP2IL1RNERAP1 | |
| SCHEMBL5180011 | 0.84 | ALDH1A1 (0.51) | KDM4EERAP2IL1RNERAP1EGLN1 | |
| SCHEMBL9609770 | 0.83 | KDM4E (0.50) | KDM4ESMN1; SMN2ALDH1A1GAA | |
| SCHEMBL29255151 | 0.82 | KDM4E (0.49) | KDM4ESMN1; SMN2ALDH1A1GAA | |
| SCHEMBL22114505 | 0.82 | KDM4E (0.49) | KDM4ESMN1; SMN2ALDH1A1GAA | |
| SCHEMBL8649103 | 0.82 | ELANE (0.51) | KDM4ESMN1; SMN2ALDH1A1L3MBTL1GAA | |
| SCHEMBL13036960 | 0.81 | EGLN1 (0.51) | KDM4ESMN1; SMN2ERAP2IL1RNERAP1 | |
| Hydrochloric Acid SCHEMBL20944983 | 0.81 | ELANE (0.50) | KDM4ESMN1; SMN2ALDH1A1L3MBTL1GAA | |
| SCHEMBL8102285 | 0.80 | ERAP2 (0.54) | ERAP2IL1RNERAP1EGLN1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE36831-E | TREATMENT OF IRON DEFICIENCY ANEMIA | BRITISH TECHNOLOGY GROUP LTD. (GB) | 2000-08-22 | — | — | US | disclosed |
| US-RE35948-E | TREATING TOXIC METAL CONCENTRATION BY ADMINISTERING N-SUBSTITUTED 3-HYDROXYPYRID-2-ONE OR 3-HYDROXYPYRID-4-ONE | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1998-11-03 | — | — | US | disclosed |
| EP-0305646-A2 | 3-Hydroxypyrid-4-ones and pharmaceutical compositions | BTG INTERNATIONAL LIMITED (GB) | 1989-03-08 | — | — | EP | disclosed |
| EP-0120670-B1 | IRON III COMPLEXES OF HYDROXYPYRIDONES, AND THEIR PHARMACEUTICAL COMPOSITIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1988-12-21 | — | — | EP | disclosed |
| US-4650793-A | NITROGEN-SUBSTITUTED | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1987-03-17 | — | — | US | disclosed |
| US-4585780-A | CHELATION OF HEAVY METALS IN BLOOD | NATIONAL RESEARCH DEVELOPMENT CORP. (GB) | 1986-04-29 | — | — | US | disclosed |